Manidipine 2HCl (also called CV-4093; CV4093), the dihydrochloride salt form of Manidipine, is a calcium channel blocker/CCB that is used clinically as an antihypertensive agent.

TG003 (TG-003; TG 003) is a novel, potent, selective and ATP-competitive Cdc2-like kinase (Clk) inhibitor with potential anticancer activity.

Prexasertib (also known as LY2606368) is a novel, potent, selective and ATP competitive inhibitor of the CHK1 (checkpoint kinase 1) protein kinase with IC50 values of<1 nM and 8 nM for CHK1 and CHK2, respectively.

SEL120-34A hydrochloride (SEL-120-34A; SEL12034A) is a novel, potent and selective ATP-competitive inhibitor of CDK8 (Cyclin-dependent kinase 8) with anticancer activity.

CDK4/6-IN-4 (Abemaciclib metabolite M20; LSN3106726) is an active metabolite of Abemaciclib, which is a CDK4/6 inhibitor with anticancer effects.

NU6027 (NU-6027; NU 6027) is a novel, potent and ATP competitive ATR/CDK (ataxia telangiectasia and Rad3-related/Cyclin-dependent kinases) inhibitor with potential antitumor activity.

BS-181 HCl is a novel, highly selective, and small molecule CDK7 inhibitor with IC50 of 21 NM in a cell-free assay.

(S)-CR8 trihydrochloride, an analog of Roscovitine, is a novel, potent 2nd-generation cyclin-dependent kinase (CDK) inhibitor, also acting as a molecular glue degrader that depletes cyclin K.

Voruciclib (formerly known as P1446A-05) is a potent and orally bioavailable CDK4/cyclin-dependent kinase 4 inhibitor with potential anticancer activity.

Palbociclib Isethionate (formerly known as PD0332991; PD-0332991; Ibrance), the isethionate salt of Palbociclib, is an orally bioavailable pyridopyrimidine-based inhibitor of CDK4/6 with potential antitumor activity and was approved as an anticancer drug.